210. Single Ventricle Clinical trials / Disease details

Clinical trials : 49 / Drugs : 53 - (DrugBank : 23) / Drug target genes : 32 - Drug target pathways : 67

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03430583 (ClinicalTrials.gov)	February 20, 2018	22/1/2018	Evaluation of Fontan-Associated Liver Disease	Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study	Single Ventricle Heart Disease	Drug: MZ101	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	12 Years	N/A	All	100		United States;Canada
2	NCT03013751 (ClinicalTrials.gov)	January 2017	5/1/2017	A Extension Study of Udenafil in Adolescents	A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation	Functional Single Ventricle Heart Disease	Drug: Udenafil	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	12 Years	18 Years	All	300	Phase 3	United States;Canada;Korea, Republic of
3	NCT02741115 (ClinicalTrials.gov)	July 22, 2016	10/4/2016	Fontan Udenafil Exercise Longitudinal Assessment Trial	Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)	Single Ventricle Heart Disease	Drug: Udenafil;Drug: Placebo	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Completed	12 Years	18 Years	All	400	Phase 3	United States;Canada;Korea, Republic of
4	NCT02201342 (ClinicalTrials.gov)	July 2014	24/7/2014	Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents	A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation	Single Ventricle Heart Disease After Fontan Surgery	Drug: Udenafil	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart Network;National Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart Network	Completed	14 Years	18 Years	Both	36	Phase 1/Phase 2	United States;Canada